Report topline data from the pivotal Phase 3 NORSE TWO study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- August 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021”
What we found
Evidence strength A What the grades mean
The company reported topline results for the NORSE TWO Phase 3 clinical trial in August 2021, which is within the third quarter of 2021.
-
A Outlook Therapeutics, Inc. 10-K filed 2021-12-23
“NORSE TWO is our pivotal Phase 3 clinical trial comparing ONS-5010 to ranibizumab (LUCENTIS) that reported highly statistically significant topline results in August 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- NORSE TWO study data
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Outlook Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-OTLK-023808 · Corrections policy